Ordering Recommendation

Aids in differentiation of inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) and other functional disorders of the gastrointestinal (GI) system. Aids in monitoring IBD and prediction of relapse.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Stool.

Specimen Preparation

Transfer 5 g stool to an unpreserved stool transport vial (ARUP Supply #40910). Available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787. (Min: 1 g)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Specimens in media or preservatives.

Remarks
Stability

Ambient: Unacceptable; Refrigerated: 7 days; Frozen: 30 days

Methodology

Quantitative Chemiluminescent Immunoassay (CLIA)

Performed

Sun-Sat

Reported

1-4 days

Reference Interval

49 µg/g or less Normal
50-120 µg/g Borderline elevated, test should be re-evaluated in 4-6 weeks.
121 µg/g Elevated

Interpretive Data

Fecal Calprotectin is an indicator of the presence of neutrophils in stool and is not specific for IBD. Other intestinal ailments including GI infections and colorectal cancer can result in elevated concentrations of calprotectin. The diagnosis of IBD cannot be established solely on the basis of a positive calprotectin result. Patients with IBD fluctuate between active and inactive stages of disease. Calprotectin results may also fluctuate.

Compliance Category

FDA

Note

Hotline History

N/A

CPT Codes

83993

Components

Component Test Code* Component Chart Name LOINC
3002862 Calprotectin, Fecal 38445-3
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Cal pro
  • Calpro
  • Fecal Calprotectin
  • IBD
  • IBS
  • Stool Calprotectin
Calprotectin, Fecal by Immunoassay